Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks, ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks
B: Arm Label: Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Placebo+Pegylated-interferon-alfa-2a+Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated-interferon-alfa-2a, Drug: Placebo, Drug: Ribavirin | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon-alfa-2a; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin
C: Arm Label: A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: PSI-7977 (GS7977); Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1, Arm 3

Answer: A